Claims for Patent: 9,458,466

Summary for Patent: 9,458,466

Title:	Translational control system using RNA-protein interaction motif
Abstract:	A translational control method using an RNA-protein interaction motif is provided. The method comprises a step of introducing an mRNA having: a 5\'UTR regulation structure comprising: (1) a cap structure at the 5\' terminus, (2) a spacer positioned on the 3\' side of the cap structure, and (3) one or more RNA motifs positioned on the 3\' side of the spacer, which comprises an RNA-protein interaction motif-derived nucleotide sequence or a variant thereof; and a nucleotide sequence encoding a target protein gene on the 3\' side of the 5\'UTR regulation structure, into a cell in the presence of a protein specifically binding to the RNA motifs, wherein a translational level is decreased as the number of bases of the spacer decreases, and the translational level is decreased as the number of the RNA motifs increases.
Inventor(s):	Saito; Hirohide (Kyoto, JP), Endo; Kei (Kyoto, JP), Inoue; Tan (Kyoto, JP)
Assignee:	Kyoto University (Kyoto, JP)
Application Number:	14/415,009
Patent Claims:	1. An mRNA comprising: a 5' UTR regulation structure comprising: (1) a cap structure at the 5' terminus; (2) one or more RNA motifs positioned on the 3' side of the cap structure, of an RNA-protein interaction motif-derived nucleotide sequence or a variant thereof; and (3) an ON switch cassette, said ON switch cassette comprising (a) a bait open reading frame (a bait ORF), (b) an intron comprising a human beta globin intron or a chimeric intron, and (c) an internal ribosome entry site (IRES); and a nucleotide sequence positioned on the 3' side of the 5' UTR regulation structure and having a nucleotide sequence encoding a gene of a target protein, wherein the bait ORF is a sequence comprising a stop codon in more than 320 bases from the intron; wherein said ON switch cassette is positioned on (a) 3' side of the RNA motif if the 5' UTR regulation structure comprises one RNA motif structure; or (b) 3' side of the RNA motif positioned at 3' end of the RNA motifs if the 5' UTR regulation structure comprises two or more RNA motifs; wherein the mRNA is an artificially prepared non-natural mRNA; wherein said human beta globin intron comprises a nucleotide sequence of Seq. ID No. 18; wherein said chimeric intron comprises a nucleotide sequence of Seq. ID No. 83. 2. The mRNA according to claim 1, wherein the bait ORF is a sequence comprising a stop codon inserted at the 457th and/or 466th base from the 5' side of Renilla luciferase; wherein said Renilla luciferase comprising a nucleotide sequence of Seq. ID No. 17 or Seq. ID No. 81. 3. The mRNA according to claim 1, wherein the intron is human .beta. globin intron. 4. The mRNA according to claim 1, wherein each of the RNA motifs is a binding sequence selected from the group consisting of a binding sequence of L7Ae protein, a binding sequence of MS2 phage coat protein and a binding sequence of Bacillus stearothermophilus ribosomal protein S15.

Details for Patent 9,458,466

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2032-07-16
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2032-07-16
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2032-07-16